Digital
9 - 10 July 2020

MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases( Time Zone - EASTERN STANDARD TIME (EST)

New medicine for orphan and Rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.

MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases scheduled to be held on 9th -10th July 2020 will provide valuable and necessary platform for uplifting knowledge at the forefront of drug analysis. Over the course of the conference, internationally-renowned speakers can describe how their analysis journeys have developed the response towards up to date challenges. The attending specialists and trade partners will offer an incredible networking expertise.

 

This conference will gather scientists, researchers, entrepreneurs, academicians, medical officers, CEO’s, CSO’s and technologists from everywhere around the globe to discuss on the newest scientific advances within the field of rare diseases & orphan drugs that facilitate to form current and future challenges in drug analysis.

WHAT TO EXPECT

Who should attend?

  • C-Level Executives, VPs/Directors, Heads, Professors, Associate professors (Biology, Biochemistry), Researchers from Pharma/Therapeutics / Biopharma and Universities- Rare diseases department
  • Patient Advocacy groups

Why attend Virtual?

  • 100+ C-level executives, Directors/VPs, Heads experts working on rare disease attending the event
  • Participate in constructive discussion with leading industry experts and decision-makers from pharmaceutical manufacturers who will tackle the most important issues in Rare disease diagnosis.
  • Best opportunity to showcase your work and research in front of industry leaders.
  • Develop your skills by learning new competencies and acquire knowledge from pioneers all around the world.

CONFERENCE AGENDA
CHALLENGES AND OPPORTUNITIES IN TREATMENT OF RARE DISEASES
PROGRESS TOWARDS FIGHTING RARE DISEASES
CONFERENCE SPEAKERS
Speakers
Scott Schliebner
Scott Schliebner
Senior Vice President, Center for Rare Diseases , PRA Health Sciences
Karen Frascello
Karen Frascello
Director, Global Medical Affairs, Early Access , Alnylam Pharmaceuticals
Dan Donovan
Dan Donovan
Founder & CEO , rareLife solutions
Dr. Michal Konstacky MD, PhD, MBA
Dr. Michal Konstacky MD, PhD, MBA
Global Medical Lead SHP 647 , Shire Pharmaceuticals
Stavros Ntogiakos
Stavros Ntogiakos
Regional Head of Rare Ocular Disease, Novartis
Pedro Lendinez Ortega
Pedro Lendinez Ortega
Key Account Manager, en Recordati Rare Diseases
Stephen Groft
Stephen Groft
Senior Advisor to the Director NCATS, , NIH
John Lagus
John Lagus
Managing Director of Business Development, Tanner Pharma Group
SPONSORS
Sponsors & Exhibitors
example-image

PRA Health Sciences

example-image

PSR

Speaking Partner
example-image

Comradis

Primary Partner
example-image

Clinigen

Conference Partner
example-image

rareLife solutions

PARTNERS
Media Partners
example-image

Hopkins Biotech Affinity Club

PAST EVENT GALLERY